13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q1 2019. See the latest, Q3 2026 →

Reported value

$11.90B

+3.3% on the quarter before

Positions

35

8 new, 10 sold out

Top 10

64.9%

of the value

Est. gain

+$1.19B

on stocks held all quarter

Est. return

+16.6%

on those stocks since Q4 2018

Filed

May 15, 2019

On SEC EDGAR ↗

Positions as of Mar 31, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2018. Striped tiles are options.

Ebay Inc9.1%
Viasat Inc8.9%
Fox Corp8.4%
Liberty Global Plc8.0%
Cheniere Energy Inc7.2%
Qorvo6.4%
Allergan Plc5.9%
11 others5.4%
Synchrony Finl3.8%
Pg&E Corp3.7%
Cbs Corp New3.4%
Celgene Corp3.2%
Mckesson Corp2.8%
Tesla2.8%
Pioneer Nat Res Co2.6%
Colony Cap Inc New2.2%
Atara Biotherapeutics Inc2.1%
Antero Res Corp2.1%
Takeda Pharmaceutical Co Ltd1.8%
Theravance Biopharma Inc1.8%
Univar Inc1.8%
Fox Corp1.7%
Akebia Therapeutics Inc1.7%
Amerisourcebergen Corp1.6%
Bristol Myers Squibb Co1.6%

Largest buys

Since Q4 2018, sized at quarter-end prices.

  1. Fox Corp~$1.00BNew, 0.0% → 8.4% of the portfolio+27,322,720 shares
  2. Celgene Corp~$377.4MNew, 0.0% → 3.2% of the portfolio+4,000,000 shares
  3. Ebay Inc~$307.7MAdded, 5.1% → 9.1% of the portfolio+8,286,000 shares
  4. Cbs Corp New~$284.9MAdded, 1.0% → 3.4% of the portfolio+5,994,957 shares
  5. Liberty Global Plc~$226.4MAdded, 5.3% → 8.0% of the portfolio+9,350,200 shares
  6. Takeda Pharmaceutical Co Ltd~$217.3MNew, 0.0% → 1.8% of the portfolio+10,669,021 shares
  7. Fox Corp~$203.8MNew, 0.0% → 1.7% of the portfolio+5,680,307 shares
  8. Bristol Myers Squibb Co~$190.8MNew, 0.0% → 1.6% of the portfolio+4,000,000 shares
  9. Pg&E Corp~$160.7MAdded, 3.2% → 3.7% of the portfolio+9,025,517 shares
  10. Mckesson Corp~$128.2MAdded, 1.6% → 2.8% of the portfolio+1,095,000 shares

Largest sells

Since Q4 2018, sized at quarter-end prices.

  1. Twenty First Centy Fox Inc~$2.47BSold out, 21.4% → 0.0% of the portfolio−51,281,167 shares
  2. Twenty First Centy Fox Inc~$814.2MSold out, 7.1% → 0.0% of the portfolio−17,040,922 shares
  3. Pioneer Nat Res Co~$380.4MCut, 5.1% → 2.6% of the portfolio−2,498,186 shares
  4. Cheniere Energy Inc~$107.9MCut, 7.3% → 7.2% of the portfolio−1,577,827 shares
  5. Ypf Sociedad Anonima~$80.3MSold out, 0.7% → 0.0% of the portfolio−6,000,000 shares
  6. Shire Plc~$80.1MSold out, 0.7% → 0.0% of the portfolio−460,473 shares
  7. Cardinal Health Inc~$65.5MSold out, 0.6% → 0.0% of the portfolio−1,467,652 shares
  8. Amc Entmt Hldgs Inc~$17.9MSold out, 0.2% → 0.0% of the portfolio−1,458,002 shares
  9. Sentinel Energy Svcs Inc~$16.5MSold out, 0.1% → 0.0% of the portfolio−1,600,000 shares
  10. Synchrony Finl~$9.3MCut, 3.0% → 3.8% of the portfolio−293,000 shares

Holdings

As of Mar 31, 2019; changes in shares since Dec 31, 2018.

Positions, sorted by share of the portfolio
HoldingValue
Ebay IncCOM · shares +39% · price +32.3%9.1%$1.09B+$190.5M
Viasat IncCOM · shares 0% · price +31.5%8.9%$1.06B+$254.7M
Fox CorpCL A COM · shares New8.4%$1.00B—
Liberty Global PlcSHS CL C · shares +31% · price +17.3%8.0%$946.4M+$106.2M
Cheniere Energy IncCOM NEW · shares −11% · price +15.5%7.2%$862.6M+$115.7M
QorvoCOM · shares −0.9% · price +18.1%6.4%$759.6M+$116.5M
Allergan PlcSHS · shares +0.3% · price +9.5%5.9%$698.3M+$60.6M
Synchrony FinlCOM · shares −2.0% · price +36.0%3.8%$454.9M+$120.4M
Pg&E CorpCOM · shares +58% · price −25.1%3.7%$436.1M−$92.1M
Cbs Corp NewCL B · shares +235% · price +8.7%3.4%$406.0M+$9.7M
Celgene CorpCOM · shares New3.2%$377.4M—
Mckesson CorpCOM · shares +64% · price +6.0%2.8%$329.5M+$11.3M
TeslaNOTE 2.375% 3/1 · shares 0% · price −9.8%2.8%$328.3M—
Pioneer Nat Res CoCOM · shares −56% · price +15.8%2.6%$304.8M+$41.6M
Colony Cap Inc NewCL A COM · shares 0% · price +13.7%2.2%$264.3M+$31.8M
Atara Biotherapeutics IncCOM · shares +2.0% · price +14.4%2.1%$253.6M+$31.3M
Antero Res CorpCOM · shares 0% · price −6.0%2.1%$252.4M−$16.0M
Takeda Pharmaceutical Co LtdSPONSORED ADS · shares New1.8%$217.3M—
Theravance Biopharma IncCOM · shares 0% · price −11.4%1.8%$211.0M−$27.2M
Univar IncCOM · shares 0% · price +24.9%1.8%$210.5M+$42.0M
Fox CorpCL B COM · shares New1.7%$203.8M—
Akebia Therapeutics IncCOM · shares 0% · price +48.1%1.7%$200.4M+$65.1M
Amerisourcebergen CorpCOM · shares +19% · price +6.9%1.6%$191.2M+$10.3M
Bristol Myers Squibb CoCOM · shares New1.6%$190.8M—
Liberty Global PlcSHS CL A · shares 0% · price +16.8%1.0%$123.5M+$17.7M
Total 35 positions100%$11.90B+$1.19B

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q4 2018 to Q1 2019: 25 stocks held throughout, up $1.19B (+16.6%).

  1. Viasat Inc+$254.7M+31%
  2. Ebay Inc+$190.5M+32%
  3. Synchrony Finl+$120.4M+36%
  4. Qorvo+$116.5M+18%
  5. Cheniere Energy Inc+$115.7M+15%
  6. Antero Res Corp−$16.0M−6%
  7. Theravance Biopharma Inc−$27.2M−11%
  8. Pg&E Corp−$92.1M−25%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free